BRCA1 and cancer: Newly diagnosed BRCA1/2 carriers (without prior clinical testing) were more likely than controls (without BRCA1/2 variants) to have EHR evidence of personal or family history of HBOC syndrome–associated cancer diagnoses (28.0% vs 53.4%) (Figure 2A and eTable 5 in the Supplement).